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Abstract
Neuroblastoma (NB) is a typical childhood and heterogeneous neoplasm for which efficient targeted therapies for high-risk
tumors are not yet identified. The chemokine CXCL12, and its receptors CXCR4 and CXCR7 have been involved in tumor
progression and dissemination. While CXCR4 expression is associated to undifferentiated tumors and poor prognosis, the
role of CXCR7, the recently identified second CXCL12 receptor, has not yet been elucidated in NB. In this report, CXCR7 and
CXCL12 expressions were evaluated using a tissue micro-array including 156 primary and 56 metastatic NB tissues. CXCL12
was found to be highly associated to NB vascular and stromal structures. In contrast to CXCR4, CXCR7 expression was low in
undifferentiated tumors, while its expression was stronger in matured tissues and specifically associated to differentiated
neural tumor cells. As determined by RT-PCR, CXCR7 expression was mainly detected in N-and S-type NB cell lines, and was
slightly induced upon NB cell differentiation in vitro. The relative roles of the two CXCL12 receptors were further assessed by
overexpressing CXCR7 or CXCR4 receptor alone, or in combination, in the IGR-NB8 and the SH-SY5Y NB cell lines. In vitro
functional analyses indicated that, in response to their common ligand, both receptors induced activation of ERK1/2
cascade, but not Akt pathway. CXCR7 strongly reduced in vitro growth, in contrast to CXCR4, and impaired CXCR4/CXCL12-
mediated chemotaxis. Subcutaneous implantation of CXCR7-expressing NB cells showed that CXCR7 also significantly
reduced in vivo growth. Moreover, CXCR7 affected CXCR4-mediated orthotopic growth in a CXCL12-producing
environment. In such model, CXCR7, in association with CXCR4, did not induce NB cell metastatic dissemination. In
conclusion, the CXCR7 and CXCR4 receptors revealed specific expression patterns and distinct functional roles in NB. Our
data suggest that CXCR7 elicits anti-tumorigenic functions, and may act as a regulator of CXCR4/CXCL12-mediated signaling
in NB.
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Introduction
Neuroblastoma (NB) is a typical pediatric neoplasm derived
from embryonic neural crest cells. The tumor recapitulates
characteristics of its originating cells, with an extensive heteroge-
neity, pluripotential differentiation and migratory abilities. The
disease displays a remarkable clinical diversity, ranging from
spontaneous regression to fatal progression and dissemination to
privileged sites, such as bone-marrow and liver [1,2].
Chemokines and their receptors have been originally described
as essential mediators of leukocyte directional migration, partic-
ularly during infection and inflammation, and have further
emerged as crucial players in all stages of tumor development
[3,4,5,6]. The binding of chemokines to their cognate receptors
elicits typical cellular responses, such as directional migration,
through activation of classical MAP-kinase or PI3-kinase/PKB
signaling cascades [7]. Both tumor and stromal cells express a large
pattern of chemokine/chemokine receptor axes, which may
represent major paracrine/autocrine complex players within the
tumor and its microenvironment [8].
CXCR4 is the most frequently expressed chemokine receptor on
tumor cells [9]. In addition to its critical role in tumor cell growth,
survival and angiogenesis in multiple cancers, the CXCR4/
CXCL12 pair has been shown to mediate homing and metastatic
secondary growth in CXCL12-producing organs, such as liver and
bone marrow [10,11,12]. However, the relative contribution of the
CXCR4/CXCL12 axis in organ-specific dissemination or/and
tumorgrowthhasbeen stronglydebated [13,14,15]. Inparticular,we
have previously shown that CXCR4 mostly promoted NB primary
tumor and secondary growth, without influencing organ-specific
dissemination of malignant NB cells [16].
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CXCR4 has long been considered as the only mediator of
CXCL12-induced biological effects. CXCR7, formerly called
RDC1, has been recently identified as an alternate receptor for
CXCL12 [17,18]. This new chemokine receptor has been
demonstrated to bind with high affinity to CXCL12 and with
low affinity to a second chemokine, interferon-inducible T cell
chemoattractant (I-TAC; also known as CXCL11). However,
despite its chemokine receptor phylogenic relation, growing
evidence has suggested that CXCR7 does not mediate typical
chemokine responses such as G protein-coupled receptor-mediat-
ed calcium mobilization [17,18,19,20]. Although coupling of the
CXCR7 receptor with G proteins is still under debate [20,21], the
possibility that the receptor is able to induce signal transduction is
nevertheless suggested by reports demonstrating MAPK and Akt
pathway activation upon CXCR7-expressing cell exposure to
CXCL12 [22,23,24]. In humans, CXCR7 is expressed in
embryonic neuronal and heart tissue, in some hematopoietic cells,
and activated endothelium [17,18,25,26,27,28,29]. Elevated levels
of CXCR7 have been detected in several tumors, and particularly
in the endothelial cell-associated vasculature [10,24,30]. More-
over, CXCR7 expression was shown to promote growth and
metastasis of various tumor models in vivo, suggesting a role for
CXCR7 in regulating immunity, angiogenesis, and organ-specific
metastasis [10,30,31]. The identification of CXCR7 has added
new perspectives for the implication of the CXCR4/CXL12 pair
in tumor biology [32,33]. However, CXCR7 specific implication
in NB dissemination, and its contribution to CXCL12/CXCR4–
mediated NB signaling are still not fully elucidated.
In this study, we investigated the expression of CXCR7 and
CXCL12 in a large panel of NB tissues. Our data revealed
a generally low CXCR7 expression in primary NBs of all stages,
which was however specifically enhanced in neural-associated
compartment of differentiated and matured tumors. In vitro and
in vivo studies showed that CXCR7 elicited anti-tumorigenic
properties, particularly in presence of CXCR4. Indeed, we
suggested that CXCR7 was sufficient to act as a regulator of
specific CXCR4/CXCL12-mediated NB growth and migration.
Altogether our data pointed to the existence of a putative cross-talk
between the two CXCL12 receptors in NB cell lines, and
suggested the implication of the global CXCR7/CXCR4/
CXCL12 axis in the regulation of NB progression.
Materials and Methods
Ethics Statement
Our study using patient tissues was approved by the ethical
research review board of the State University Hospital of
Lausanne (CHUV). Patient tissue collection and analyses were
performed after patients’ written informed consent. Animal
experimentation protocols (authorization number: 1564.1/5) were
approved by the state veterinary services.
Cell Lines
All NB well-characterized cell lines [34], the MCF-7 breast
cancer cell line [17], the PC-3 prostate cancer cell line [35], and
the SW480 colon cancer cell line [36] were cultured in Dubelcco’s
modified Eagle’s medium (D-MEM) (Gibco, Paisley, UK)
supplemented with 1% penicillin/streptomycin (Gibco) and 10%
heat inactivated Foetal Calf Serum (FCS) (Sigma-Aldrich, St
Louis, MO, USA).
Tissue-microarray (TMA)
The TMA was composed of tumor samples from 156 patients,
diagnosed with NB between July 1988 and April 2002, treated and
followed in four clinical centers: Biceˆtre hospital and Gustave
Roussy Institute (Villejuif, France), the American Hospital (Reims,
France), CHU Sainte Justine (Montre´al, Canada), and Shiga
University hospital (Otsu, Japan). Four tissue cylinders (0.6 mm
diameter) per sample were obtained and transferred into a re-
cipient paraffin block using a manual tissue arrayer (Alphelys,
Plaisir, France). Five mm sections of TMA blocks were depar-
affinated in xylol bath for 10 min, and rehydrated by successive
transfers in alcohol baths with decreasing concentration, and
finally in H20. Then, sections were washed for 5 min in 3% H2O2
to inhibit endogenous peroxydase. TMA sections were incubated
overnight at 4uC with mouse anti-human CXCL12 (clone 79018,
R&D systems, Minneapolis, MN, USA) and mouse anti-human
CXCR7 (clone 9C4, kind gift from Dr. M. Thelen, IRB,
Bellinzona, Switzerland) antibodies diluted in Dako REALTM
antibody diluent (Dako, Glostrup, Denmark). Incubation with
secondary antibody was performed using EnVisionTM HRP-
antibodies (Dako) for 30 min, followed by treatment with 100 ml
DAB (Dako) at 1/50 dilution for 8 min. Slides were then
incubated in hematoxylin bath for 10 s, and then dehydrated in
baths with increasing alcohol concentration, and finally in xylol.
Washes between each step were done in TBS pH 7.6. Slides were
mounted using Eukitt Mounting Medium (EMS, Hatfield, PA,
USA). Immunostaining scores (0–4) were established for each
stained tissue by semi-quantitative optical analysis by two in-
dependent investigators blinded for clinical data. The percentage
of positive cells in each sample was scored as follows: 0, all cells
negative; 1+, up to 25% of cells were positive; 2+, 26% to 50%;
3+, 51% to 75%; 4+, more than 75%.
RT-PCR
Total RNA, extracted from cell lines using the RNeasy Mini kit
(Qiagen, Hilden, Germany), was reverse-transcribed using Prime-
ScriptTM RT reagent Kit, according to the manufacturer’s instruc-
tions (TAKARABio Inc., Shiga, Japan).Oneml of cDNAwas added
to 5 U/ml GoTaqHHot Start Polymerase (Promega, Madison, MI,
USA), specific buffer, 0.2 mM dNTPs and 1 mM human-specific
primer pairs.ThePCRreaction consisted of 2 min at 95uC, followed
by30cyclesof30 sat95uC,30 sat60uC,and30 sat72uC,withafinal
step of 5 min at 72uC. CXCR4 and CXCR7 expression levels were
compared to those of theGAPDH housekeeping gene. PCRproducts
were analyzed on 2% agarose gels. Real-time semi-quantitative RT-
PCRwas performedusing theABI PRISM7900 HTreal-time PCR
system (Applied Biosystem) with SYBR Green detection mix
(Qiagen). Expression levels of CXCR4 and CXCR7 transcripts were
calculated relatively to the level of the housekeeping gene HPRTI
using the DDCt method. PCR program corresponded to: 2 min at
50uC,5 minat95uC,40cyclesof threerepeatedstepsofamplification
(10 s at 95uC, 30 s at 60uC, 15 s at 95uC), and 15 s at 65uC.Human-
specific pairs of primers: CXCR7:59-
TGGGCTTTGCCGTTCCCTTC-39 and 59-
TCTTCCGGCTGCTGTGCTTC-39, CXCR4:59-TATCTGT-
GACCGCTT-CTACC-39 and 59-GCAGGACAGGATGA-
CAATA-C-39, GAPDH: 59-AGATCATCAGCAATGCCTCC-39
and 59-GTGGCAGTGATGGCAT-GGAC-39, HPRT1:59-TGA-
CACTGGCAAAACAATGCA-39 and 59-GGTCCTTTTCACC-
AGCAAGCT-39.
Plasmids
The complete coding sequence of CXCR7 (1.089 kb) was
amplified by PCR from a pcDNA3 plasmid containing human
CXCR7 (kindly provided by Dr. M. Thelen, Bellinzona) using 59
and 39 primers containing XhoI and EcoRI sites as follows: sense:
59-GCGCCTCGAGATGGATCTGCATCTCTTCGACTAC-
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T-39; antisense: 59-GCGCG-AATTCTCATTTGGTGCTC-
TGCTCCA-39. The amplified cDNA was subcloned into the
pMigr vector (kind gift from F. Louache, Institut Gustave Roussy,
Villejuif, France) containing IRES-EGFP sequence. The pMigr
plasmid containing complete coding region of CXCR4 (1.1 kb) was
already used and described elsewhere [16,37]. Plasmids containing
CXCR7 and CXCR4 cDNAs were sequenced for their integrity.
The pMigr-EGFP vectors encoding for EGFP with or without
CXCR4 or CXCR7 gene was inserted by retroviral-mediated
infection into NB cells, as previously described [37].
Flow Cytometry
Transduced GFP-expressing cells were sorted by FACS AriaITM
cell sorter (BD Biosciences, San Jose, CA, USA) to control
transfection efficiency.
Single cells were stained with PE-labeled mouse anti-CXCR4
(clone 12G5, BD Biosciences), and mouse anti-CXCR7 (clone
9C4), as previously described [16,18]. Alexa FluorH 647-labeled
goat anti-mouse secondary antibody (Invitrogen, Carlsbad, CA,
USA) was used for the detection of CXCR7. Ten thousand events
were analyzed by FACScan (BD Biosciences).
Immunofluorescence
Hundred thousand cells were plated in Lab-TekR Chamber
SlideTM System (Nunc, Ny,USA), 48 h before analyses. Cells were
washed with PBS, fixed in 4% paraformaldehyde (PFA) (Fluka,
Buchs, Switzerland) for 10 min at room temperature, and then
permeabilized with SAP buffer (0.1% saponin (Sigma)20.05%-
NaN3 in PBS) for 15 min [22]. Cells were blocked in SAP buffer
supplemented with 10% goat serum (Sigma), and then incubated
with anti-CXCR7 (10 mg/mL clone 9C4, and clone 11G8 from
R&D systems) or anti-b3 tubulin (1:1000, clone 2G10, Sigma) in
SAP buffer containing 1.5% goat serum. Cells were next
incubated with appropriate Cy3-conjugated secondary antibody
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
DAPI (Sigma) was added for nuclear staining, and slides were
mounted using DAKOH Fluorescent mounting medium (Dako).
Imaging was performed using a camera DFC345 FX (Leica
Microsystems Schweiz AG, Switzerland) and analyzed with the
Leica Application Suite (LAS) software.
Differentiation Assay
In vitro neuronal and glial/shwannian differentiation assays were
performed by treating NB cells with all-trans retinoic acid (RA)
(Sigma) and bromodeoxyuridine (BrdU), respectively, as pre-
viously described [38,39,40]. RA was dissolved in DMSO to
a concentration of 3.5 mg/ml and stored in light protected vials at
220uC. Aliquots of stock solution were freshly thawed for each
experiment and diluted in DMEM, 10% FCS. NB cells were
plated 24 h before treatment with either 10 mM RA or BrdU.
Medium was renewed every three days.
ERK1/2 and Akt Phosphorylation
Following overnight serum starvation, cells were either un-
stimulated or stimulated with 100 ng/mL human recombinant
CXCL12 or CXCL11 (PeproTech, Rocky Hill, NJ, USA) for
indicated time, or pre-treated with 1 mM of the specific CXCR4
blocker 4F-benzoyl TN14003 (kind gift of N.Fujii, Kyoto, Japan)
prior to ligand stimulation. Cells were lysed in sample buffer
(250 mM Tris-HCl at pH 6.8, 10% SDS, 40% Glycerol, 16% b-
mercaptoethanol, 0.04% Bromo-phenol-blue), and protein lysates
were loaded on 10% SDS-PAGE. Gels were transferred to
Immobilon-P membranes (Millipore, Volketswil, Switzerland).
Membranes were blocked in TBS-Tween 0.01% containing 2%
ECL AdvanceTM Blocking Agent (AmershamTM ECL AdvanceTM
Western Blotting Detection Kit, GE Healthcare, Buckingham-
shire, UK), and blotted with specific primary antibodies: rabbit
anti-phospho-p44/42 MAPK (thr202/Tyr204), rabbit anti-phos-
pho-Akt (Ser 473), rabbit anti-p44/42 MAPK, rabbit anti-Akt (all
from Cell Signaling, Danvers, MA, USA). Blots were then
incubated with the appropriate HRP-conjugated secondary
antibody (Dako). ECL detection kit (GE Healthcare) was used
for detection.
Soft Agar Assay
Anchorage-independent colony formation assay, modified from
a previous protocol [41], was performed using double-layer soft
agar in 6-well plates (Corning) with a top layer of 0.175% agar
(DifcoTM Agar Noble, BD Biosciences) and a bottom layer of
0.35% agar. Briefly, 56103 NB cells were suspended in 0.175%
agar diluted in DMEM/10% FCS, and laid on the top of the
supporting agar layer. When stipulated, 100 mL fresh medium
supplemented with 100 ng/mL CXCL12 was added weekly.
Colonies were allowed to form at 37uC for at least two weeks.
Colony cell viability was assessed using the MTS/PMS cell
proliferation kit (Promega), and viable colonies were counted using
light microscopy (Leica Laborluc D).
Chemotaxis Assay
Cell migration was measured using Transwell CostarH cell
culture chambers with polycarbonate filters of 8 mm porosity
(BD Biosciences), as previously described [16]. 26105 cells
suspended in DMEM/2% FCS were seeded in the upper
compartment of the chamber system. The lower compartment
was filled with DMEM/2% FCS supplemented or not with
100 ng/ml CXCL12 (PrepoTech). The cells were allowed to
settle down for 4 h. After washing with PBS, membranes were
fixed for 10 min in 4% PFA (Fluka) in PBS. Membranes were
stained with haematoxylin (Polysciences, warrington, PA, USA).
Non-migrated cells were carefully scraped from the upper side
of the filter, and migrated cells on the lower side were counted
by light microscopy.
In vivo Studies
All animal experiments were carried out with Swiss athymic
nude mice (Balb/C nu/nu). For heterotypic assays, groups of three
mice were subcutaneously injected in the flank with 26105 cells
suspended in 200 ml mix (1:1) of DMEM and BD MatrigelTM
Basement Membrane Matrix (BD Biosciences). The grafted
animals were then weekly monitored with calipers for tumor
growth assessment. The tumor volume was calculated using the
formula (length6width2)/2. For orthotopic assays, seven animals
per cell line were engrafted with NB cells directly in the left
adrenal gland, as previously described [16,37]. Briefly, 56105 cells
in 15 ml DMEM were injected in the adrenal gland using a 22G
needle connected to a Hamilton syringe. Tumor take and growth
were followed by ultrasound imaging every 10 days, at the
Lausanne Cardiovascular Assessment Facilities. Macroscopic
metastases were assessed by gross examination.
CXCL12 ELISA
Cultured NB cells were harvested and suspended in RIPA lysis
buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 10% glyce´rol,
1.5 mM MgCl2, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 100 mM NaF), supplemented with a protease inhibitor
cocktail (Complete mini, EDTA-free, Roche, Mannheim, Ger-
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many). Snap frozen tumors and mouse tissues were cut in small
pieces and suspended in the above described lysis buffer. Samples
were sonicated for 30 s, followed by a centrifugation step for
15 min at 20’000 g. Total protein amount was quantified using
the Bradford method (Biorad Laboratories, Richmond, CA, USA).
CXCL12 expression levels were quantified using a CXCL12
ELISA kit (R&D Systems) according to the manufacturer’s guide.
Statistical Analyses
Statistical analyses were performed using GraphPadPrism 5.0
(GraphPad Software Inc., San Diego, CA, USA). *p,0.05
represented significance; **p#0.01 and ***p#0.001 were inter-
preted to be highly significant.
Results
Expression of CXCR7 and CXCL12 in NB Tissues
A NB TMA including a panel of 156 primary NB tumors, 56
metastatic and 65 control normal tissues, such as adrenal glands
(AG) and sympathetic ganglia (SG), was screened for CXCR7 and
CXCL12 expression. Patient clinical data and associated tumors
are detailed in Table 1. The expression of CXCR7 or CXCL12
was semi-quantitatively assessed as an immunostaining score (0–4)
in three distinct cell populations in each tissue: the neural,
endothelial and stromal compartments. Neuroblasts and tumor
ganglion cells were included in the neural compartment of tumors,
while adrenal medulla and normal ganglion cells represented the
neural part of AG and SG, respectively. Fibroblasts in tumors and
AG, and Schwann cells in tumors and SG were attributed to the
stroma.
CXCR7 is preferentially expressed by mature neural cells
in differentiated and matured tumors. A low CXCR7
expression (median score of 0.92) was observed in neural cell
compartment in 76% of NB primary tumors (PTs), while no
CXCR7 expression (all median scores ,0.5) was detected in the
vascular and stromal compartments of PTs, metastatic and control
tissues (Figure 1A, Table 2). Thus, CXCR7 staining, albeit low,
was generally localized in the neural compartment of NBs.
Interestingly, CXCR7 expression did not correlate with NB grades
(Table S1), but significantly enhanced with tumor differentiation
stage (Figure 1B, 1C). Neural-associated CXCR7 staining score
was significantly enhanced in differentiated tumors, such as
ganglio-neuroblastomas (GGNBs) (median score of 0.9360.65,
p,0.05) and ganglioneuromas (GGNs) (median score of
1.6260.64, p,0.01), when compared to undifferentiated NBs
(UnNBs) (median score of 0.5760.37). In particular, our data
showed that CXCR7 staining was associated to tumor ganglion
cells (black arrow) in GGNBs and GGNs, while no staining was
observed in normal SG tissues. Moreover, CXCR7 expression
increased in tumors from less than 1 year-old patients (Figure 1D),
whom are known to present tumors with the potential to regress
spontaneously, or to mature into benign matured tumors, such as
GGNs [2]. Despite these observations, the TMA analyses did not
allow to assign CXCR7 a statistically significant favorable
prognosis value (data not shown).
CXCL12 is associated to the vascular and stromal
structures of NBs. The CXCL12 ligand was strongly ex-
pressed in endothelial cells (red arrow) in all PTs (median score of
3.12), and highly associated to the stroma (median score of 1.97),
while weakly expressed in the neural compartment (median score
of 0.82) in NB PTs (Figure 1A, 1E, Table 2). In particular, tumor
endothelial cells expressed higher levels of CXCL12 when
compared to normal tissues (Table 2). Although, vascular
CXCL12 expression was found independent of NB clinical stages
(Table S1), it increased in tumors from patients over one year-old,
whom are known to potentially present aggressive tumors [2]
(Figure 1F). Even though high and similar CXCL12 levels were
observed in the stromal compartment of tumors and controls
(mean scores of 1.9, Table 2), ligand expression was further
enhanced in the schwannian stroma of GGNBs, and, albeit not
statistically significant, of GGNs (Figures 1E, 1G). In addition,
chemokine expression, even low, was enhanced in the neuroblastic
compartment of metastatic samples as compared to PTs, and in
PTs as compared to controls (Table 2).
Table 1. TMA: clinical characteristics.
Patient at diagnosis N=156
Age (mo)
Median (range) 26 (0–151)
,12 mo, n (%) 78 (50)
$12 mo, n (%) 78 (50)
Follow-up (mo)
Median (range) 101 (1–243)
Survival
Alive at time of last follow-up, n (%) 117 (75)
INSS stage
1, n (%) 31 (20)
2, n (%) 19 (12)
3, n (%) 32 (21)
4, n (%) 58 (37)
4S, n (%) 16 (10)
COG Risk Classification
Low, n (%) 54 (35)
Intermediate, n (%) 44 (28)
High, n (%) 58 (37)
Neuroblastoma type
Standard, n (%) 101 (65)
Mass screening, n (%) 55 (35)
Sample type
Primary tumor, n 156
Metastasis, n 56
Lymph node, n (%) 48 (86)
Liver, n (%) 6 (10)
Skin, n (%) 2 (4)
Control normal tissue, n 65
Adrenal Gland, n (%) 50 (77)
Sympathetic ganglion, n (%) 15 (23)
Differentiation Stage
UnNB, n (%) 36 (23)
GGNB, n (%) 20 (12)
GGN, n (%) 6 (3)
mo: month.
n: number of cases.
INSS: International Neuroblastoma Staging System.
COG: Children Oncology Group.
NB: neuroblastoma.
UnNB: undifferentiated NB.
GGNB: ganglioneuroblastoma.
GGN: ganglioneuroma.
doi:10.1371/journal.pone.0043665.t001
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Expression of the CXCR7 Receptor in NB Cell Lines
CXCR7 expression in N-, S-and I-type NB cell lines. To
corroborate our TMA analyses, we next assessed CXCR7
expression by RT-PCR analyses in well-characterized NB cell
lines harboring neuronal-like (N-type), glial/schwannian-like (S-
type), or intermediate and undifferentiated (I-type) phenotype
[1,34]. In contrast to CXCR4, CXCR7 expression was not detected
in any analyzed I-type NB cell lines (SK-N-Be(2c), LAN-5, SH-
IN), while 4/8 N-type cell lines (IGR-N91, LAN-1, IMR-32, SJN-
B12) and 1/2 S-type cell line (SH-EP) expressed the receptor
(Figure 2A). Moreover, poor CXCR7 surface expression was
detected in RT-PCR-positive NB cells, while only IMR-32 cells
harbored significant levels of both CXCL12 receptors (Figure 2B).
Thus, our data suggested that, as observed in tumor tissues,
CXCR7 expression may be linked to NB cell differentiated
phenotype, as no CXCR7 expression was detected in the most
undifferentiated NB cell lines.
CXCR7 expression may be associated with NB cell
differentiation in vitro. As we observed a stronger CXCR7
expression in differentiated tumor tissues, we next investigated
whether the receptor expression could bealso associatedwithNBcell
differentiation in vitro. Consequently, we induced CXCR7-negative
NB cell lines to differentiate in vitro, by using all-trans retinoic acid
(RA) and bromodeoxyuridine (BrdU) [38,42,43]. As N-and I-type
NB cell subtypes have been shown to progress towards neuronal or
glial/schwannian fateuponRAorBrdUtreatment, respectively[44],
N-type IGR-NB8andSH-SY-5Y cells, aswell as I-type SK-N-Be(2c)
cells were exposed to 10 mM of either differentiation agent for
30 days. NB cell morphology changes appeared as early as 3 days
after either RA or BrdU exposure (right panel, Figure 2C), and
persisted during all the differentiation induction experiment (Figure
S1A), aspreviouslyobserved [44].Moreover, treatedNBcells elicited
global reduced proliferation, without enhanced apoptosis, further
confirming an induced differentiation of treated NB cells in vitro
(Figure S1B and S1C). As shown in Figure 2C (left panel), CXCR7
expression was induced in IGR-NB8 cells after 3 days of RA
treatment (p,0.01), whereas its expression was weakly detectable
upon BrdU exposure. Similar RA-induced CXCR7 expression
pattern was also detected in the SH-SY5Y and the SK-N-Be(2c) cell
lines (Figure S2A, S2B). These data thus suggested that induction of
CXCR7 expression, albeit weak, preferentially occurred when NB
cells underwent neuronal rather than glial/schwannian differentia-
tion. Addition of CXCL12 together with RA or BrdU treatment did
not further increase receptor expression in treated NB cells (Figure
S2B). However, induced CXCR7 protein levels might be too low, or
post-translationallymodified, as they could be neither detected at the
cell surface (FACS analyses), nor in the intracellular space of treated
NB cells (Immunofluorescence assays), by both anti-CXCR7
antibodies used in this study (data not shown).
Ectopic expression of CXCR7 in NB cell lines. Although
CXCR7 was found in a minority of NB cell lines as compared to
CXCR4, its expression was however detected in some CXCR4-
expressing NB cells. Consequently, we next focused on the
individual roles and functional interactions between CXCR7 and
CXCR4 in NB. To that extent, individual CXCR7, CXCR4 or
combined receptors were overexpressed in the CXCR4/CXCR7-
negative IGR-NB8 cell line (respectively NB867, NB8x4 and
NB86467 cell lines). CXCR7 was also ectopically overexpressed
in the SH-SY5Y cell line (SHSY67 cells), which expresses high
endogenous CXCR4 levels (Figure 2D). Of note, a decrease of
CXCR7 surface expression was observed in SHSY67 cells (mean
fluorescent intensity of 44) as compared to NB86467 cells (mean
fluorescent intensity of 60), while similar CXCR4 surface
expression was detected in these two cell lines. Different CXCR7
Figure 1. Expression of CXCR7, and its ligand CXCL12 in a NB TMA. (A) Semi-quantitative assessment of CXCR7 and CXCL12 expression levels
in neural, endothelial and stromal cell compartments of NB primary tumors. Median score represents the average of the immunostaining score (0–4).
Percentage (%) indicates percentage of CXCR7-or CXCL12-positive tumor tissues. (B) Immunohistochemical analysis of CXCR7 in undifferentiated
tumor (UnNB), ganglioneuroblastoma (GGNB), ganglioneuroma (GGN) and control normal sympathetic ganglion (SG) tissues. Black arrow: ganglion
cell. (C) CXCR7 expression levels (median score) in UnNBs, in differentiated tumor tissues, (D) and in tumors of patient according to the age of patient
at diagnosis. (E) Immunohistochemical analysis of CXCL12 in UnNBs, GGNBs, GGNs and SG tissues. Red arrow: endothelial cell. (F) CXCL12 expression
levels (median score) in the endothelial compartment of tumors according to the age of patient at diagnosis, (G) and in the stroma of UnNBs, GGNBs
and GGNs. Student’s t-test: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0043665.g001
Table 2. Expression of CXCR7 and CXCL12 in NB primary tumors, metastases and control tissues.
Neural cells Endothelial cells Stromal cells
Primary tumor Metastasis Control Primary tumor Metastasis Control Primary tumor Metastasis Control
CXCR7 expression
Positive tissues (%) 76 75 63 33 33 26 58 53 24
Number of cases 119 42 41 52 19 17 92 30 16
Median score 0.92 0.93 0.78 0.15 0.18 0.14 0.48 0.45 0.2
p-value ns ns ns ns ns 0.01
CXCL12 expression
Positive tissues (%) 77 92 70 100 100 100 98 98 93
Number of cases 121 52 46 156 56 65 153 55 61
Median score 0.82 1.04 0.59 3.12 3.13 3 1.97 1.93 1.98
p-value 0.02 0.01 ns 0.01 ns ns
Control regroups normal adrenal gland and sympathetic ganglion tissues; Median score means average tumor score, as established by semi-quantitative analysis of the
immunostaining; p-value (Student’s t-test) refers to primary tumor: ns means not significant, p,0.05 is considered significant, p#0.01 is considered very significant.
doi:10.1371/journal.pone.0043665.t002
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expression levels in these two double receptor-expressing cell lines
were confirmed by semi-quantitative RT-PCR analyses
(Figure 2E). Thus, the two CXCR7/CXCR4-expressing trans-
duced cell lines harbored variable relative expression levels of the
two CXCL12 receptors.
CXCL12 and CXCL11 Induce ERK1/2, but not Akt Pathway
Activation in CXCR7-expressing NB Cells
As CXCR7/CXCL12-mediated ERK1/2 activation was de-
tected in various models [22,23,45,46], we next assessed ERK1/2
cascade activation in NB transduced cells, in response to either
CXCL12 or CXCL11 ligand. We showed herein that ERK1/2
was activated in CXCR4-and CXCR7-transduced NB cells after
CXCL12 stimulation, indicating that CXCR4 and CXCR7 were
both able to activate downstream pathways in response to their
common ligand (Figure 3A). Interestingly, constant ERK1/2
activation was maintained until 30 min after CXCL12 stimulation
in NB8x4 cells, whereas enhanced intensity after 5 and 10 min,
followed by a signal decrease was observed in the NB867 and
NB8x467 cell lines. These data indicated that CXCR7 might
interact with CXCR4/CXCL12-mediated signaling. Moreover,
ERK1/2 activation was lost in CXCR4-expressing NB864 cells
upon addition of the specific CXCR4 inhibitor (TN14003), further
confirming that this activation was specific and restricted to the
CXCR4/CXCL12 axis in those cells. As ERK1/2 activation was
not completely inhibited by TN14003 treatment in
NB86467 cells, it further suggested that ERK1/2 activation
was partially mediated by the CXCR7/CXCL12 axis in CXCR7/
CXCR4-expressing NB86467 cells. In parallel, CXCR7 only
slightly weakened CXCR4/CXCL12-induced ERK1/2 activation
Figure 2. Expression of the two CXCL12 receptors in NB cell lines. (A) Qualitative RT-PCR analyses for CXCR7 and CXCR4 mRNA expression in
a panel of N-, I-and S-type NB cell lines. GAPDH was used as gene of reference. The prostate cancer cell line PC-3 and the breast cancer cell line MCF-7
were used as positive controls for CXCR7 expression. (B) Flow cytometry analyses of CXCR7 and CXCR4 cell surface expression in NB cell lines. Percent
represents CXCR7-or CXCR4-positive cells. Grey line: cells stained without the primary Ab. Black line: cells stained with anti-CXCR7 or anti-CXCR4. (C)
Semi-quantitative real-time PCR analyses of CXCR7 mRNA expression level in the IGR-NB8 cell line after 3 days of treatment with either 10 mM RA or
BrdU (left panel). Expression levels of CXCR7 transcripts were calculated relatively to the level of the housekeeping gene HPRTI. Untreated (unt.) cells
and DMSO-treated NB cells represented control conditions. Columns indicate results in triplicates, and were representative of two independent
experiments. Error bars indicate S.D. Student’s t-test: *p,0.05, **p,0.01. Images (right panel) represent immunofluoresence staining of b3-tubulin
(red) and DAPI (blue) in treated or untreated IGR-NB8 cells. (D) CXCR7, CXCR4, or a combination of the two CXCL12 receptors was overexpressed in
the IGR-NB8 and the SH-SY5Y cell lines. As all vectors encoded for EGFP, transduced GFP-expressing NB cells were sorted by FACS to control
transfection efficiency. Both NB8pMigr and SHSYpMigr cell lines represented control cells, transduced with the pMigr empty vector. Percent of
CXCR7-and CXCR4-positive transduced cells are indicated as well as the mean fluorescent intensity (brackets) for CXCR7 and CXCR4 staining. Dark
and grey lines: cells stained without anti-CXCR7 and anti-CXCR4, respectively; Green and blue lines: cells stained with anti-CXCR7 and anti-CXCR4,
respectively. (E) Semi-quantitative real-time PCR analyses for CXCR7 mRNA expression levels in NB transduced cell lines. Experiment was performed in
triplicates. Error bars indicate S.D.
doi:10.1371/journal.pone.0043665.g002
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in the other double receptor-positive SHSY67 cell line, and was
not able to signal via ERK1/2 upon addition of both CXCL12
and CXCR4 inhibitor (Figure 3B). In addition, CXCR7 was also
able to activate ERK1/2 cascade in NB867 and NB86467 cells
upon CXCL11 engagement (Figure 3C), but not in SHSY67 cells
(data not shown). These data thus suggested that the two CXCR7/
CXCR4-expressing SHSY67 and NB8x467 cell lines differently
responded to CXCL12 and CXCL11.
Looking for additional downstream effectors of CXCR7 and
CXCR4 receptors, we also evaluated Akt activation upon
stimulation of NB cells with either CXCL12 or CXCL11
chemokine ligand [10,47]. However, neither the CXCR4/
CXCL12 nor the CXCR7/CXCL12/CXCL11 axes were able
to activate Akt in transduced NB cells (Figure S3).
In Contrast to CXCR4, CXCR7 Alters NB Growth in vitro
As the CXCR7 receptor was shown here to activate growth-
regulating pathway such as ERK1/2 cascade, we next explored
the role of CXCR7, and analyzed the relative contribution of the
two CXCL12 receptors in mediating NB growth in vitro. Our data
showed that the presence of CXCR4 significantly enhanced
NB864 and NB86467 cell clonogenic abilities, while CXCR7
expression in NB867 cells resulted in significantly decreased
colony number, when compared to the NB8pMigr cell line, and in
absence of the ligand (Figure 4A, upper panel). Interestingly, the
Figure 3. ERK1/2 activation in NB cell lines. Immunobloting of phospho-ERK (pERK) and total ERK (ERK) in transduced cells, treated with (A, B)
100 ng/ml human recombinant CXCL12, in presence or in absence of 1 mM of the CXCR4 blocker TN14003, (C) 100 ng/ml human recombinant
CXCL11.
doi:10.1371/journal.pone.0043665.g003
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presence of CXCR7 also significantly decreased the number of
colonies derived from the SHSY67 cell line, in absence and in
presence of CXCL12 (Figure 4A, lower panel). Addition of the
ligand markedly increased the clonogenic capacity of the CXCR4-
positive SHSYpMigr cell line, without affecting that of SHSY67
cells. These data thus suggested that CXCR7 affected the
CXCR4-mediated SHSY67 growth, but not that of
NB86467 cells in vitro.
CXCR7 Impairs CXCR4/CXCL12-mediated NB Chemotaxis
The CXCR7/CXCL12 axis has been proposed to induce
tumor cell migration in various cancer models [10,46,48].
Therefore, we next evaluated the impact of CXCL12 binding to
CXCR7 on NB chemotaxis in vitro. No migration toward the
ligand CXCL12 was observed using CXCR7-expressing
NB867 cells and CXCR7/CXCR4-expressing NB86467 and
SHSY67 cells (Figure 4B). In contrast, the presence of CXCL12
significantly enhanced motility of CXCR4-expressing cells
(NB864 and SHSYpMigr cells), as previously described [16].
Thus, these data showed that the CXCR7/CXCL12 pair could
not stimulate NB chemotaxis, and further suggested CXCR7 as
a negative regulator of CXCR4 signaling, as it altered CXCR4/
CXCL12-mediated chemotaxis of NB cells in vitro.
CXCR7 Abrogates Subcutaneous NB Growth
We next addressed the impact of CXCR7 on NB growth in vivo,
and particularly its ability to regulate and/or impair the CXCR4-
mediated effects. In subcutaneous conditions, overall tumor take
was reduced in the group of mice engrafted with NB867, as only
3/6 sites presented a tumor versus 6/6 sites for the other groups
(Figure 5A). The volume of NB867 cell-derived tumors was also
significantly reduced, as compared to that of derived from the
control NB8pMigr cell line. Supporting our in vitro observations,
these data further suggested CXCR7 as a critical player in NB
growth regulation. However, H&E staining analyses did not reveal
particular differentiation area on paraffin-embedded sections of
NB867 cell-derived xenografts (data not shown). In addition,
growth of NB8 cell-derived tumors was not significantly affected
by the presence of CXCR4 alone, nor in association with CXCR7
in such in vivo conditions.
To evaluate a putative functionality of the CXCL12 ligand in
CXCR7-mediated effect in our heterotypic mouse model, we
measured the concentration of CXCL12 in s.c xenografts, and
associated NB transduced cell lines (Figure 5B). As CXCL12 was
highly produced in mouse adrenal gland tissues [16], production
levels of the chemokine in such tissues were used as positive
control. CXCL12 production in NB cell lines and xenografts was
low (mean concentration of CXCL12,180 pg/mg of protein) and
did not significantly vary between either cell lines or derived
tumors, suggesting that the CXCR7-mediated anti-proliferative
effect is unlikely due to the presence of its ligand CXCL12 in such
in vivo conditions.
Figure 4. Impact of CXCR7 on NB growth and migration in vitro. (A) Clonogenic growth of NB transduced cell lines was evaluated in a soft
agar assay, after at least two weeks of incubation at 37uC. Columns: mean values 6 SEM of two independent experiments. When stipulated, 100 ng/
mL CXCL12 were added to the culture medium. (B) Chemotaxis of transduced NB cells toward 100 ng/ml CXCL12. Columns: mean values6 SEM of at
least two independent experiments. Student’s t-test was used for all experiments: *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0043665.g004
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CXCR7 Delays CXCR4-mediated Proliferative Effect in
Orthotopic Conditions
As we showed herein that CXCR7 enabled NB growth
reduction in a heterotypic mouse model (Figure 5A), and altered
CXCR4/CXCL12-mediated NB migration (Figure 4B), we
further evaluated the extent to which CXCR7 would affect both
the in vivo CXCR4-mediated growth promoting effect and NB
dissemination in a orthotopic environment. To that purpose,
NB864 and NB86467 cells were orthotopically implanted in
mouse adrenal gland, as previously described [16], and tumor
growth was evaluated by echography for 6 weeks (Figure 5C). At
week 3, 33% of animals engrafted with NB864 cells developed
a tumor, whereas no tumors were detected in the NB86467
group. Interestingly, the volume of NB86467 cell-derived tumors
was significantly reduced as compared to that of the NB864 group
at week 5 (p,0.05), suggesting that CXCR7 significantly affected
tumor take of tumors derived from CXCR4-positive
NB86467 cells. Due to excessive tumor volume in the NB864
group, mice had to be sacrificed at earlier time point (week 5) than
those injected with the NB86467 cell line (week 6). At week 6, 6/
7 mice in the NB86467 group developed tumors, with volume
similar to those observed at week 5 with the NB864 group. No
macroscopic metastases were observed in either group.
Discussion
The CXCR4/CXCL12 axis has been largely shown to
participate in tumor development and progression [9,16].
Although several hypotheses on the role of CXCR7 and its
possible interaction with CXCR4 have been proposed in different
tumor systems, the functional implication of the global CXCL12/
CXCR7/CXCR4 axis in NB remains unknown. Our TMA
analyses revealed that CXCR7 expression was generally weak in
primary NB of all stages and in metastatic tissues. Moreover, in
contrast to breast, lung and hepatocellular carcinomas, CXCR7
was not expressed in NB vasculature but rather preferentially
associated to its neural compartment [30,49]. Interestingly,
CXCR7 expression was associated to mature neural cells, such
as ganglion cells, in stroma-rich GGNB and GGN tumors, which
are associated to a favorable prognosis [2]. However, no
statistically significant favorable prognosis value could be assigned
to CXCR7. The absence of significance may be explained by the
low and variable levels of CXCR7 expression in heterogeneous
NB tissues. Nonetheless, the particular CXCR7 expression pattern
Figure 5. Impact of CXCR7 on NB growth in vivo. (A) In vivo tumor take (number of sites with tumor/total sites) and growth (mean tumor
volume 6 SEM) after s.c implantation of transduced NB cells in nude mice. Two-way ANOVA: **p,0.01. (B) Production of CXCL12 was measured by
ELISA in transduced NB cell lines, and derived s.c tumors. Normal nude mouse adrenal gland (AG) tissue was used as positive control. Results are
expressed in triplicates as pg of CXCL12 per mg of extracted protein. Error bars indicate S.D. of triplicates. (C) In vivo orthotopic implantation of
NB864 and NB86467 cell lines in nude mice. Upper panel: tumor take represented as fraction and percentage of tumor-bearing mice from week 3
to week 6 after NB cell implantations. Lower panel: kinetics of tumor volume. Mann-Whitney test: *p,0.05.
doi:10.1371/journal.pone.0043665.g005
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on mature cells suggested an implication/association of the
CXCR7 receptor with NB differentiation.
Interestingly, TMA analyses also revealed a strong CXCL12
expression in endothelial and stromal cells in tumors, suggesting
a paracrine role of the chemokine in NB. In particular, a putative
implication of the ligand in NB angiogenesis is likely, as already
reported in the context of ovarian and colon cancers [50,51].
The pattern of CXCR4 expression in NB has been already
shown to be related to high stage disease, including non-metastatic
stage 3 and metastatic stage 4 NBs [52]. As the two receptors
elicited specific expression patterns in NB tissues, our TMA
analyses suggest a complex contribution of the CXCR7 and
CXCR4 receptors in NB pathogenesis, which may be tightly
modulated by a permanent cross-talk with their common ligand
CXCL12, highly produced by tumor microenvironment.
Screening of NB cell lines by RT-PCR analyses revealed specific
CXCR7 expression in N-type and S-type NB cell lines, rather than
in the most undifferentiated I-type NB cell lines [53], suggesting an
association of CXCR7 expression with neuronal-and/or glial/
schwannian NB cell phenotype. A link between CXCR7
expression and cell differentiation phenotype has already been
reported in immune cells. CXCR7 expression was indeed
proposed to correlate with dendritic cell maturation, and described
as a potential maker of differentiating memory B cells [54].
Moreover, CXCR7 expression has been also shown to drastically
increase in FCS-induced differentiation of glioma cells in vitro [45].
A weak induced CXCR7 expression was observed in NB cells
exposed to RA, but not to BrdU, suggesting that CXCR7 may be
associated with neuronal rather than glial differentiation. These
in vitro analyses correlated our TMA data showing CXCR7
staining in tumor ganglion cells, rather than in schwannian
stroma. However, CXCR7 could be neither detected at the
surface, nor in the intra-cellular space of NB cells during all the
differentiation induction experiment. These observations suggest
that receptor expression may be modulated by potential post-
translational modifications, or that putative induced-protein
expression is too low to be detected by antibodies used in this
study. In addition, exogenous CXCR7 did not induce, by its own,
phenotypic changes in the slow proliferating-tumors in our
heterotypic mouse model. Indeed, no ganglion-like cells and no
differentiating neuroblasts were detected in NB8x7-derived
xenografts. Therefore, further investigation will be necessary to
determine the intimate link between CXCR7 expression and NB
differentiation process.
Although specifically expressed in differentiated and matured
tumors, CXCR7 was also detected in a weak percentage of tumor
cells in tissues, independently of NB clinical stages. As CXCR4 is
largely expressed in high grade NBs, co-expression of the two
CXCL12 receptors in tumor tissues is then likely. Screening of NB
cell lines confirmed such hypothesis by showing co-expression of
CXCR7 and CXCR4 in some NB cells, as described elsewhere
[55]. Consequently, we next examined the role of CXCR7 in NB,
and particularly its relation with CXCR4. CXCR7, like CXCR4,
was able to induce downstream signaling pathway on its own.
However, co-expression of the two receptors in NB cells led to
a modulation of ERK1/2 activation in presence of CXCL12,
demonstrating a functional interaction between CXCR7 and
CXCR4 in NB, as described in other models [56]. However,
induction of ERK activation by either CXCL12 or CXCL11
appeared to be cell line-dependent, as NB8x4x7 and SHSYx7 cells
responded differently towards these chemokines. Such discrepancy
may result from CXCR4 endogenous expression levels, from
variable CXCR7 exogenous levels detected in these NB cell lines,
or suggests that CXCR7 may signal through pathways other than
ERK1/2 cascade in NB cells.
In contrast to CXCR4, CXCR7 alone significantly decreased
in vitro NB cell clonogenic potential, in absence of CXCL12.
Furthermore, CXCR7, by its own, also significantly reduced
subcutaneous growth of NB cell-derived tumors, independently of
its ligand. Such data are further supported by a recent study
showing that proliferation of CXCR7-positive glioma cells may
not be affected by CXCL12 [45]. In addition, a ligand-in-
dependent role for CXCR7 has been also demonstrated in
a prostate cancer model [57]. Therefore, CXCR7 and CXCR4
might individually display opposite ligand-independent-mediated
functions in NB.
Significant in vitro alterations of NB clonogenicity were noted in
the SHSY67 cell line expressing both CXCR7 and CXCR4
receptors, in presence or in absence of CXCL12. In an orthotopic
and CXCL12-producing environment, CXCR7 was not able to
suppress the growth of large, established tumors, as growth curve
slopes of both NB864 and NB86467 cell-derived tumors were
similar in the exponentially tumor growth phase. However, in such
environment and in contrast to s.c. conditions, presence of
CXCR7 clearly resulted in a delayed tumor take of CXCR4/
CXCR7-positive cell-derived tumors, as compared to NB864 cell-
derived tumors. Consequently, our observations suggest a critical
role of CXCR7 in regulating CXCR4-mediated effects in NB, and
underline the essential impact of a particular microenvironment
on NB cell behavior, as mentioned in our previous study [16].
CXCR7 alone did not favor migration of NB cells toward
CXCL12, in contrast to CXCR4. Conversely, a very recent study
reported that CXCR7 enhanced chemotaxis of CXCR7-expres-
sing NB cells in presence of CXCL12-producing mesenchymal
stromal cells [55]. However, it was not clear whether additional
factors released by stromal cells were required for truly activating
NB chemotaxis. More interestingly, CXCR7 significantly altered
the CXCR4-mediated chemotaxis of NB86467 and SHSY67
cells toward CXCL12, further supporting a negative regulation of
CXCR4 by CXCR7.
It has been recently proposed that CXCR7 may control
CXCL12 distribution by sequestrating the ligand present in the
extracellular space. In such model, CXCR7 enables establishment
of effective CXCL12 gradients, thus resulting in increased
responsiveness of CXCR4 signaling and chemotaxis in response
to these gradients [58,59]. In that context, CXCR7 has been
clearly demonstrated to control cell migration in a zebrafish
model, and to regulate migratory advantage provided by CXCR4
in CXCR4/CXCR7-expressing primary T cells and tumor cells
[32,59,60,61]. However in the present study, co-expression of
CXCR7 with CXCR4 apparently did not favor metastatic
dissemination of a non-aggressive IGR-NB8 cell line in vivo, as
no metastases were detected after orthotopic implantation of
NB86467 cells. In the other hand, ligand-scavenging effect
attributed to CXCR7 has been also proposed to limit acute
CXCR4/CXCL12-mediated signaling. Indeed, Hernandez et al
suggested that CXCR7 scavenging function might impair
CXCR4-induced breast tumor cell invasion, by down-regulating
CXCR4/CXCL12-mediated metalloproteinase-12 production
[33]. As altered CXCR4/CXCL12-mediated chemotaxis and
growth were observed upon co-expression of the two CXCL12
receptors in NB cells, such ligand scavenging role for CXCR7
appears likely, and may enable a negative regulation of CXCR4/
CXCL12-mediated fonctions in NB.
CXCR7 was also reported to act as a co-receptor for CXCR4.
Combined CXCR4/CXCR7 expression has been detected in
primary human tumors and tumor cell lines [45,62,63]. Structural
Role of the Two CXCL12 Receptors in Neuroblastoma
PLOS ONE | www.plosone.org 11 August 2012 | Volume 7 | Issue 8 | e43665
association of the two receptors has been shown to affect CXCR4/
CXCL12-mediated G-protein signaling [64]. As ERK cascade
activation was modulated in CXCR4/CXCR7-expressing NB
cells as compared to CXCR4-expressing NB cells, putative
heterodimerization of the two receptors in NB cells is thus
possible. Moreover, it has been hypothesized that CXCR7, once
engaged in heterodimers with CXCR4, may also negatively
regulate CXCR4 functions through an allosteric mechanism
(independently of CXCL12) [64]. These observations further
support our data showing an alteration of the CXCR4-mediated
growth promoting effect in vitro in SHSYx7 cells, particularly in
absence of CXCL12. Several lines of evidence have suggested that
chemokine receptor homo-or heterodimerization activates distinct
signaling pathways, and thus distinct biological responses [65]. As
the two CXCL12 receptors may form heterodimers as efficiently
as homodimers [64], tight regulation of CXCR4 and CXCR7
expression may enable variable conformations of the two receptors
at cell membrane, and may thus lead to activation of distinct
signaling [66,67]. Such hypothesis may explain the heterogeneity
of responses observed in vitro, using the two transduced NB cell
lines expressing variable CXCR7/CXCR4 receptor expression
levels.
To conclude, our data reveal distinct functional roles for the two
CXCL12 receptors in NB. While CXCR4 favors NB growth and
chemotaxis, CXCR7 reduces tumor growth and may be associated
to less aggressive stages of the disease. Our data clearly show anti-
tumorigenic properties for the CXCR7 receptor in NB, as
CXCR7 was able to affect in vitro migration-promoting effect
mediated by the CXCR4/CXCL12 axis, and to delay orthotopic
tumor take of CXCR4-positive NB cells. Taken together our
observations suggest that CXCL12-induced responses may result
from a direct or indirect cross-talk between CXCR7 and CXCR4,
which may be tightly modulated by receptor expression and by
a particular ligand-producing microenvironment. However,
whether CXCR7 may modulate CXCR4 signaling as a result of
their heterodimerization or/and by scavenging the ligand will
need further investigation. Nonetheless, a putative cross-talk
between the two CXCL12 receptors may give clues to elucidate
the original and complex CXCR7/CXCR4/CXCL12 distribu-
tion and functions in NB pathogenesis.
Supporting Information
Figure S1 Characteristics of NB cells after RA or BrdU
treatment in vitro. (A) SK-N-Be(2c) cells were exposed to either
10 mM all-trans Retinoic Acid (RA) or 5-bromo-2-deoxyuridine
(BrdU) for 3 and 30 days. Images illustrate immunofluoresence
staining of b3-tubulin (red) and DAPI (blue). RA-treated NB cells
elaborated enhanced neuritic processes and proliferated by
forming interconnected cell clumps, while BrdU-treated cells
presented glial-like morphology, with large flat cytoplasm and
enhanced surface adherence. Morphological changes were not
detected in untreated (unt.), nor in DMSO-treated control cells. (B)
Growth of SK-N-Be(2c) (left panel) and IGR-NB8 (right panel)
cells was followed upon treatment with either differentiation agent
for 96 h. Columns represent OD mean 6 SEM of two
independent experiments. As previously described [44], RA
enhanced SK-N-Be(2c) cell growth for 72 h, as compared to cells
exposed to DMSO, before inducing a growth arrest in those cells
at 96 h. Proliferation of IGR-NB8 cells already slowed down after
72 h of RA treatment, as compared to DMSO-treated control
cells. BrdU-treatment induced a reduction of both SK-N-Be(2c)
and IGR-NB8 cell growth, as compared to untreated cells. (C)
Apoptosis was measured by detection of the sub-G1 apoptotic cell
using the PI staining method [68]. Such assay was performed after
7 day-treatment with either 10 mM RA or BrdU. Treatment of
NB cells with 1 mg/ml doxorubycin (Dox) for 48 h was used as
positive control. A slight induction of mortality was noted for the
SK-N-Be(2c) cell line when treated with RA, which was also
previously reported [44], while no effect was observed upon
treatment with BrdU, as compared to control cells. None of the
treatments induced apoptosis of IGR-NB8 cells.
(TIF)
Figure S2 CXCR7 mRNA expression levels upon differ-
entiation of NB cells in vitro. (A) Semi-quantitative real-time
PCR analyses of CXCR7 mRNA expression levels upon treatment
of SH-SY5Y cells with 10 mM RA or BrdU for 3 days. (B) The
SK-N-Be(2c) and the IGR-NB8 cell lines were treated with 10 mM
RA. Untreated cells (unt.) or cells exposed to DMSO were used as
controls. When stipulated, 100 ng/mL CXCL12 were added to
the culture medium. Expression levels of CXCR7 transcripts were
calculated relatively to the level of the housekeeping gene HPRTI.
The breast cancer cell line MCF-7 and the prostate cancer cell line
PC-3 were used as positive controls for CXCR7 expression.
Columns indicate results in triplicates and were representative of
two independent experiments. Error bars indicate S.D. Student’s
t-test: *p,0.05, **p,0.01.
(TIF)
Figure S3 Akt pathway activation in NB cell lines.
Immunobloting of phospho-Akt (pAkt) and total Akt (Akt) in NB
transduced cells, stimulated with (A) 100 ng/ml CXCL12, or (B)
100 ng/ml CXCL11 at indicated time points. NB transduced cells
were also treated with 10 ng/ml IGF-1 for 1 h, as positive control
[69].
(TIF)
Table S1 Expression of CXCR7 and CXCL12 in NB
clinical groups. CXCR7 and CXCL12 expression, as associ-
ated to neural, endothelial and stromal cell compartments, were
measured in INSS neuroblastoma clinical groups.
(DOC)
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